© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert Joel Neal, MD, PhD, speaks to the management of a 64-year-old man diagnosed with EGFR exon20 insertion–positive NSCLC.
April 21st 2022
A case of a 64-year-old man with non–small cell lung cancer, who tested positive for an EGFR exon 20 insertion mutation after progression on frontline therapy.
Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.
Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.
A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.
The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.
Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.
Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing.